U.S. Markets closed

Proxy Advisors Could Tilt the Scales in the Bristol-Celgene Deal. Watch for Their Calls Next Week.

Evie Liu

Management and shareholders at Bristol-Myers Squibb continue to spar over the firm’s proposed acquisition of Celgene. Recommendations from proxy-advisory firms will be critical to whether the deal goes ahead.